Polyrizon Ltd. PLRZ
Medical/Dental Instruments · IPO 2024 · data as of November 13, 2026
Polyrizon Ltd. (PLRZ) is a healthcare company listed in the US with a market value of about $27M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -1872%.
About Polyrizon
Polyrizon is listed in the US and classified in medical/dental instruments, IPO year 2024. It was profitable in 0 of the last 4 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$3M | -$2M | -$600000 | -$779000 |
| Free cash flow | -$5M | — | — | -$1M |
| EPS (diluted) | $-1.37 | $-0.64 | $-0.25 | $-0.32 |
| Net margin | — | — | — | — |
| ROIC | -23.5% | -19.5% | -5573.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Polyrizon pay a dividend?
Not currently.
Is Polyrizon a good stock to buy?
We do not give buy or sell advice. Polyrizon scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.